Company Description
Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible.
The Company’s Endosomal Escape Vehicle (EEV™)-therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index.
Through this proprietary, versatile and modular approach, Entrada is advancing a robust development portfolio of RNA- and protein-based programmes for the potential treatment of neuromuscular and ocular diseases, among others.
The company was formerly known as CycloPorters, Inc., and changed its name to Entrada Therapeutics, Inc., in October 2017.
Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
| Country | United States |
| Founded | 2016 |
| IPO Date | Oct 29, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 183 |
| CEO | Dipal Doshi |
Contact Details
Address: One Design Center Place, Suite 17- 500 Boston, Massachusetts 02210 United States | |
| Phone | 857 520 9158 |
| Website | entradatx.com |
Stock Details
| Ticker Symbol | TRDA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $20.00 |
| CIK Code | 0001689375 |
| CUSIP Number | 29384C108 |
| ISIN Number | US29384C1080 |
| Employer ID | 81-3983399 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dipal Doshi | Chief Executive Officer and Director |
| Nathan J. Dowden | President and Chief Operating Officer |
| Dr. Natarajan Sethuraman Ph.D. | President of Research and Development |
| Kory James Wentworth CPA | Chief Financial Officer and Treasurer |
| Dr. Jared Cohen J.D., Ph.D. | General Counsel |
| Kerry Robert M.S. | Senior Vice President of People |
| Karla MacDonald | Chief Corporate Affairs Officer |
| Kevin Healy Ph.D. | Senior Vice President of Regulatory Affairs |
| Sandeep Basnet | Head of Information Technology |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 14, 2025 | SCHEDULE 13G/A | Filing |
| Aug 14, 2025 | SCHEDULE 13G/A | Filing |
| Aug 6, 2025 | 10-Q | Quarterly Report |
| Aug 6, 2025 | 8-K | Current Report |
| Jul 9, 2025 | 144 | Filing |
| Jul 9, 2025 | 144 | Filing |
| Jul 1, 2025 | 144 | Filing |
| Jul 1, 2025 | 144 | Filing |
| Jun 30, 2025 | 144 | Filing |
| Jun 30, 2025 | 144 | Filing |